Charlotte Parker, Author at Oral Cancer News

Rx Target Found For HPV, Hep C And Related Cancers

Article Date: 15 Apr 2013 - 0:00 PDTSource: Medical News Today New discoveries by a team of scientists at LSU Health Sciences Center New Orleans for the first time reveal the inner workings of a master regulator that controls functions as diverse as the ability of nerve cells to "rewire" themselves in response to external stimuli and the mechanism by which certain viruses hijack normal cellular processes to facilitate their replication that can ultimately lead to cancer. The research was published in the Journal of Biological Chemistry. The complex genetic programs controlling the function of cells and the organs, nerves, and tissues that they form are expressed through the concerted contributions of some 30,000 unique proteins that constitute the human genome. Coordination of these proteins is controlled by a small set of master regulators that sense the environment of the cell and alter subtle features of the genetic programs to maintain metabolic balance, called cellular homeostasis. More radical alterations in the genetic programs due to gene mutation or in response to viral or bacterial infection frequently lead to conditions that can result in cancer or developmental defects. Lead investigator Dr. Virginia Ronchi, a postdoctoral fellow, and research associate Jennifer Klein, working in the laboratory of Dr. Arthur Haas, Professor and Head of Biochemistry and Molecular Biology at the LSU Health Sciences Center New Orleans School of Medicine, focused on the E6AP enzyme. This enzyme regulates the functions of several dozen different proteins involved in key homoeostatic processes. The E6AP protein belongs [...]

Charlotte Parker2013-05-09T13:10:26-07:00May, 2013|Oral Cancer News|

Radiosensitive Variation Key in HPV-Positive Head and Neck Cancer

Kate JohnsonMay 01, 2013Source: medscape.com GENEVA, Switzerland — Increased radiosensitivity likely contributes to improved outcomes in patients human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HNSCC), according to a new study. The findings point to a potential new approach that could enhance radiosensitivity further in these tumors, said Thorsten Rieckmann, PhD, from University Medical Center Hamburg Eppendorf in Germany. The study results, which he presented here at the 2nd European Society for Radiotherapy & Oncology (ESTRO) Forum, were also published online April 19 in Radiation and Oncology. The work was named 1 of 2 top-scoring abstracts at the ESTRO meeting. Dr. Rieckmann and colleagues compared a panel of 5 HPV-positive and 5 HPV-negative HNSCC cell lines, and demonstrated a statistically significant difference in average radiosensitivity between the 2 panels. However, in the HPV-positive cells, "we saw a very high variation in radiosensitivity, so clearly not every HPV-positive cell line is equally highly radiosensitive," Dr. Rieckmann told meeting delegates. "Therefore, caution should be urged when considering the deintensification of therapy via dose reduction," the researchers write. "Additional stratification within the subentity of HPV/p16-positive HNSCC may be necessary to more precisely predict individual tumor sensitivity." "Until we have molecular markers to predict radiosensitivity in HPV-positive HNSCC, pack-years of smoking, as suggested by Ang et al [N Engl J Med. 2010;363:24-35], are probably the best option," he told Medscape Medical News. The study demonstrated that a compromised DNA repair process is likely the reason behind the more favorable prognosis for patients with HPV-positive HNSCC treated [...]

Charlotte Parker2013-05-02T10:12:42-07:00May, 2013|Oral Cancer News|

Be a trendsetter for oral cancer screenings

By Trish De Dios April 18, 2013Source: dentistryiq.com April is Oral Cancer Awareness Month. We are well-trained in hygiene school to perform a non-invasive visual and tactile oral cancer screening. We perform it on every patient we see and the patients of our school clinic are accustomed to the comprehensive nature of the exam we perform. We then are set free from the chains of dental hygiene school and unleashed into the world of professional private practice. Unfortunately, the transition from school to work can cause us to cut corners and be negligent in our oral cancer screening, due in part to the demands of being in private practice. Employers are often apprehensive of the time constraints of the exam and may be misinformed regarding how screenings would take place in their practice. My advice to the new grad is stay true to your ethical and clinical standards of care. Do not deviate from being thorough in your oral cancer screenings because of your newly acquired degree or work position. The most important part of a patient’s hygiene visit is this potentially life-saving exam, and once your patients and employer realize this, they will never undermine your clinical protocol. In addition to the great service you are providing your patients, it is a good business practice to create value in the dental hygiene appointment. Your patients are not just getting their teeth cleaned – convey to your employer and patients that when you are their hygienist, the hygiene visit will consist [...]

Charlotte Parker2013-04-24T16:51:37-07:00April, 2013|OCF In The News, Oral Cancer News|

HPV vaccination—reaping the rewards of the appliance of science

Source: bmj.comDate: April 18, 2013By: Simon Barton, clinical director National programmes could virtually eliminate certain diseases and substantially reduce costs. The optimism generated by scientific breakthroughs often turns to disappointment when applied to the real world of clinical care. It is therefore worth celebrating the extraordinary success of Australia’s national human papillomavirus (HPV) vaccination programme, which was implemented five years ago, as reported in the linked paper by Ali and colleagues (doi:10.1136/bmj.f2032).1 This analysis of data on 85 770 new patients from six Australian sexual health clinics shows a remarkable reduction in the proportion of women under 21 years of age presenting with genital warts—from 11.5% in 2007 to 0.85% in 2011 (P<0.001). Only 13 cases of genital warts were diagnosed in women under the age of 21 across all six health clinics in 2011. Such a reduction in this distressing disease caused by a sexually transmitted virus is a major public health achievement. Furthermore, the near eradication of genital warts in young Australian women will probably have a major impact on the costs of sexual healthcare. In 2007, Australia became one of the first countries to implement a nationally funded HPV vaccination programme for girls and young women with the quadrivalent vaccine. It started with the vaccination of girls aged 12 years in schools and a catch-up programme for girls and women aged 13-26 years. Quadrivalent vaccine protects against HPV types 6 and 11, which cause more than 90% of genital warts, in addition to HPV types 16 and 18, which [...]

Charlotte Parker2013-04-22T12:13:42-07:00April, 2013|Oral Cancer News|

Robotic surgery vs. radiation, chemo for throat cancer, study to see which is best

By: Sheryl Ubelacker, The Canadian Press, April 17, 2013Source: ottawacitizen.com TORONTO - It was quite a shock for Rod Sinn when he learned the persistent sore throat he'd had for five months, initially diagnosed as tonsillitis, was actually an increasingly common form of throat cancer caused by the human papilloma virus. Equally unpleasant was the news that the standard treatment for oropharyngeal cancer, which typically affects the back of the tongue, tonsils and nearby tissues, is radiation and chemotherapy. Sinn, a physically fit non-smoker who only drinks alcohol occasionally, had seen what the double-barrelled treatment could do. A friend diagnosed with throat cancer a year earlier and given the standard treatment lost his salivary glands and sense of taste. "I thought, wait a minute, there's got to be another option. I really don't like the side-effects of all that radiation," the 52-year-old businessman, who lives in Oakville, Ont., near Toronto, said Tuesday. After searching the Internet, he discovered doctors at Western University in London, Ont., were the only ones in Canada performing robotic-assisted surgery for throat cancer. Sinn had the robotic surgery in spring 2011, plus a follow-up operation to remove some lymph nodes for testing to make sure his cancer hadn't spread. While the surgery left him unable to swallow for several weeks and he lost some taste buds for a time, he is virtually back to normal except for some numbness in his neck where the lymph nodes were removed. "It was fantastic," said Sinn, who counts himself a believer [...]

Charlotte Parker2013-04-18T16:40:32-07:00April, 2013|Oral Cancer News|

Researchers Design Drug to Restore Cell Suicide in HPV-Related Head and Neck Cancer

Source: sciencedaily.comDate: April 8, 2013 Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy. HPV-positive head and neck cancer has become three times more common since the 1970s, and it could reach epidemic levels in the future, say researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) who led the study. "We believe these findings will help meet the real need for more effective and safer therapy for a growing number of HPV-positive head and neck cancer patients," says principal investigator Dr. Quintin Pan, associate professor of otolaryngology at the OSUCCC -- James. The study was published in the journal Oncogene. The research, which mainly used head and neck cancer cells, shows that a protein produced by the virus blocks a protein made by the host cell. The cell protein, called p300, regulates a gene called p53. This gene both controls cell division and protects the body against cancer by causing cells to die before they become malignant. By blocking the cell protein, HPV forces the host cell to live instead of die and to proliferate and form tumors. The prospective new drug, called CH1iB, prevents the viral protein from binding [...]

Charlotte Parker2013-04-09T15:09:21-07:00April, 2013|Oral Cancer News|

Dental groups dispute Consumer Reports cancer screening story

Source: http://www.drbicuspid.comBy: Donna Domino, Features EditorDate: April 5, 2013 The dental community is up in arms over a recent Consumer Reports article that claims oral cancer screening is one of several medical tests that are overrecommended and unnecessary for all but high-risk patients. The article, which appears in the March 2013 issue, concluded that "most people shouldn't waste their time" on most diagnostic tests, including chairside visual screenings for oral cancer. "Most people don't need the test unless they are at high risk, because the cancer is relatively uncommon," Consumer Reports wrote. But the ADA and the Oral Cancer Foundation vehemently disagree with the magazine's conclusions, asserting that visual screening can result in earlier diagnosis of oral cancer and other oral diseases. The Consumer Reports article recommends only three cancer tests -- cervical, colon, and breast -- as worthwhile, and includes oral cancer screening among "eight to avoid" tests: ovarian, pancreatic, testicular, prostate, bladder, lung, oral cavity, and skin cancer. The magazine said its ratings were based mainly on reviews from the U.S. Preventive Services Task Force. Early diagnosis critical According to Consumer Reports, the medical community has "systematically exaggerated" the benefits of screening while downplaying the harms, such as unnecessary radiation and biopsies. The ADA quickly registered its disappointment with the recommendations and sent a letter -- co-signed by the American Academy of Oral & Maxillofacial Pathology -- to the editors of Consumer Reports, noting that noninvasive visual and tactile oral cancer screenings are typically included in oral exams [...]

Charlotte Parker2013-04-23T15:24:32-07:00April, 2013|OCF In The News, Oral Cancer News|

Cancer clinics are turning away thousands of Medicare patients. Blame the sequester.

Posted by Sarah Kliff on April 3, 2013 at 5:46 pmhttp://www.washingtonpost.com Ralph V. Boccia of the Center for Cancer and Blood Disorders runs a cancer clinic that is in danger of losing funding due to the sequester cuts. (Sarah L. Voisin/The Washington Post) Cancer clinics across the country have begun turning away thousands of Medicare patients, blaming the sequester budget cuts. Oncologists say the reduced funding, which took effect for Medicare on April 1, makes it impossible to administer expensive chemotherapy drugs while staying afloat financially. Patients at these clinics would need to seek treatment elsewhere, such as at hospitals that might not have the capacity to accommodate them. “If we treated the patients receiving the most expensive drugs, we’d be out of business in six months to a year,” said Jeff Vacirca, chief executive of North Shore Hematology Oncology Associates in New York. “The drugs we’re going to lose money on we’re not going to administer right now.” After an emergency meeting Tuesday, Vacirca’s clinics decided that they would no longer see one-third of their 16,000 Medicare patients. “A lot of us are in disbelief that this is happening,” he said. “It’s a choice between seeing these patients and staying in business.” Some who have been pushing the federal government to spend less on health care say this is not the right approach. “I don’t think there was an intention to disrupt care or move it into a more expensive setting,” said Cathy Schoen, senior vice president of the [...]

Charlotte Parker2013-04-05T13:41:32-07:00April, 2013|Oral Cancer News|

Roger Ebert Announces Return Of Cancer, Says He’s Taking ‘Leave Of Presence’

By: Tom Kludt Date: 9:46 AM EDT, Wednesday April 3, 2013Source: http://livewire.talkingpointsmemo.com Pulitzer Prize-winning film critic Roger Ebert announced Tuesday evening in a post on his Chicago Sun-Times blog that he has suffered a return of cancer. As a result, Ebert — who has written prolifically in recent years on a host of topics other than just cinema — said he will be taking a "leave of presence." "What in the world is a leave of presence? It means I am not going away," Ebert wrote. "My intent is to continue to write selected reviews but to leave the rest to a talented team of writers handpicked and greatly admired by me. What's more, I'll be able at last to do what I've always fantasized about doing: reviewing only the movies I want to review." In 2012, Ebert said he penned 306 movie reviews, one or two blog posts per week and "assorted other articles" — a higher output than any other point in his career. The blog post commemorated the 46th anniversary of Ebert joining the Sun-Times as a film critic. Ebert suffered a hip fracture in December, which led to the latest diagnosis of cancer. He was diagnosed with thyroid cancer in 2002, and in 2006 he lost his ability to speak after his carotid artery burst during a surgery to remove cancer located in his jaw. The latest health episode, Ebert wrote, will likely color his writing going forward. "At this point in my life, in addition to [...]

Charlotte Parker2013-04-03T10:54:36-07:00April, 2013|Oral Cancer News|

Major study finds no link between vaccines and autism

Source: therawstory.comBy: Agence France-Presse Date: Friday, March 29, 2013 A US study out Friday sought to dispel the fears of about one third of American parents that giving a series of vaccines to children may be linked to autism. Even though children are receiving more vaccines today than they did in the 1990s, there is no link between “too many vaccines too soon” and autism, said the study in the Journal of Pediatrics. About one in 10 US parents refuse or delay vaccinations for their children because they believe it is safer than following the schedule put out by the Centers for Disease Control and Prevention, according to previous research. Prior studies have already shown there is no link between vaccines and autism, including a 2004 comprehensive review by the Institute of Medicine. This time, researchers at the CDC decided to look children’s exposure to antigens, the substances in vaccines that cause the body to produce antibodies to fight infection and disease. Researchers looked at data from 256 children with autism spectrum disorder across three separate managed care organizations in the United States. They compared the cumulative exposure to antigens in those children to 752 children without autism. “We found no evidence indicating an association between exposure to antibody-stimulating proteins and polysaccharides contained in vaccines during the first two years of life and the risk of acquiring autism spectrum disorder, autism disorder or autism spectrum disorder with regression,” said the study. Nor were there any links between autism and cumulative [...]

Charlotte Parker2013-03-29T13:14:29-07:00March, 2013|Oral Cancer News|

Oral Cancer News
Compiled by The Oral Cancer Foundation

About Charlotte Parker